A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
4 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors'. Together they form a unique fingerprint.

Medicine & Life Sciences